Source of the article: Heart Future; Editor: Zhang Yuqing
Reprint Requirements: If the source of the article is indicated at the beginning of the text, it can be reprinted directly.Recently,Yellwin (referred to as "Yellwin")Yellwin Announces Completion of Nearly 100 Million Yuan in Series A+ Financing. This round of financing follows Yellwin's completion of Series A financing in April 2023.The second round of financing completed rapidly within a year,The company will continue to strengthen the research and development and market promotion of its cardiac surgery and heart failure product lines.
In the new phase of medical device innovation and development, the leading role of scientists and clinical experts is becoming increasingly prominent. Independent innovation based on clinical needs and more efficient collaboration between medical and engineering fields are effective ways to break through the "internal competition" in the medical device industry.Yellwin was founded by a team of clinical experts in cardiac surgery from Anzhen Hospital, together with senior technical experts from the cardiovascular device industry both in China and abroad.Stand,The team has accumulated over 20 years of clinical and product development experience in cardiac surgery and heart failure, possessing not only extensive expertise in the diagnosis and treatment of heart disease surgery, a deep understanding of clinical pain points and patient needs, but also profound insights into the current issues and development trends of cardiovascular medical devices in China, especially in the field of coronary heart disease.The team, starting from clinical needs, has been committed to creating products that not only meet the requirements of clinical work but also fill the market gaps in China's medical device-related fields. At the same time, the products align with national healthcare policy directions, helping to accelerate the innovation process for domestically produced high-end medical devices in China, assisting doctors in improving clinical outcomes while reasonably controlling treatment costs.Under the combined influence of centralized procurement, the pandemic, and an aging population, China's cardiac surgery field is gradually showing two major trends:One is the increasingly intensified contradiction between the supply of hospital-based diagnosis and treatment capabilities and the demand for patient visits; the other is the growing trend of patients developing severe conditions and surgeries becoming more complex.And with the development of China's socio-economy, changes in the lifestyle of its citizens, as well as the acceleration of aging population and urbanization, the impact of cardiovascular disease risk factors on residents' health has become increasingly significant, with the incidence of cardiovascular diseases continuing to rise. However, the majority of cardiothoracic surgical medical devices still rely on imports, and the industry is in urgent need of domestically produced alternatives.The development levels of cardiac surgery and cardiology in China are imbalanced, with a significant gap compared to foreign advancements. There are challenges such as a lack of tools, high costs, and issues in preoperative diagnosis, intraoperative support, and postoperative quality control.Since its establishment, the company has consistently adhered to commercialization capabilities and innovation as the core of product development. In a relatively short period, it has rapidly laid out commercially viable products, giving the company the potential to quickly form a closed-loop business model. At the same time, it balances investment in innovative flagship products and long-term planning, achieving a perfect equilibrium between rapid commercialization and innovative R&D.Currently, the companyProducts such as a new generation of heart stabilizers, femoral artery-vein catheters, and an intelligent coronary angiography scoring system are about to obtain registration certificates and enter the commercial sales phase.In areas such as animal experiments and nursing, multiple short-cycle rapid commercialization projects have been laid out, enhancing the company's self-sustaining capabilities.At the same time, the company actively increases the continuous investment in its leading products, constantly building up its innovation barriers.Coronary Artery Bypass Quality Control SystemHas entered the experimental production phase,Pulsatile Left Ventricular Assist Systemhave completed the design finalization. This product will fill the clinical gap in China and accelerate the development of domestically produced high-end medical devices for cardiac surgery.Yellwin's self-developedPulsatile Percutaneous Left Ventricular Assist Device (PVAD)It is developed based on the clinical pain points in severe cardiac surgery treatment, while also meeting the diagnostic and treatment needs of patients with cardiogenic shock in cardiology scenarios.
Yellwin's PVAD product not only has the advantages of low cost, high safety, and no need for DSA assistance like IABP products, but also addresses the issue of insufficient flow in traditional pulsatile PVAD products such as IABP and PulseCath. The product aims to complement continuous-flow PVAD products represented by IMPELLA, providing Chinese cardiologists with a powerful, domestically innovated tool to manage high-risk patients.
Yellwin was founded in 2021,It is an innovative enterprise focusing on the research and development of devices in the field of cardiac surgery and heart failure.Based on the founding team's many years of clinical experience in cardiac surgery, the company has tapped into clinical needs and developed multiple medical devices by integrating the current state of related fields. This fills the clinical gap and accelerates the trend of domestically produced high-end medical devices in cardiac surgery.
As of the date of publication, the company's financing history is as follows:
As of the date of publication, the following partial patent information of the company has been queried:
Editor-in-Chief | Zhao Qing Reviewed by | Yi He
